皓宸医疗(002622) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥82,485,669.07, representing a 395.85% increase compared to ¥16,635,191.36 in the same period last year[3] - The net profit attributable to shareholders was -¥25,339,030.73, a decrease of 693.98% from -¥3,191,400.03 year-on-year[3] - The total operating revenue for the first quarter of 2022 was ¥82,485,669.07, a significant increase from ¥16,635,191.36 in the same period last year, representing a growth of 394.4%[18] - The net loss for the first quarter was ¥36,395,477.46, compared to a net loss of ¥3,191,400.03 in the previous year, reflecting a deterioration in performance[20] - The total comprehensive loss for the first quarter was ¥36,704,772.00, compared to a loss of ¥7,329,294.08 in the previous year[21] - Basic and diluted earnings per share were both reported at -¥0.0302, a decline from -¥0.0038 in the same quarter last year[21] Cash Flow - The net cash flow from operating activities was -¥32,253,006.95, a decline of 892.49% compared to ¥4,069,851.03 in the previous year[3] - The cash flow from operating activities showed a net outflow of ¥32,253,006.95, contrasting with a net inflow of ¥4,069,851.03 in the same quarter last year[22] - The company reported a net cash inflow from investing activities of ¥54,470,751.65, primarily from the recovery of investments totaling ¥55,000,000.00[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,719,382,737.43, down 4.06% from ¥1,792,171,860.35 at the end of the previous year[3] - Total current assets decreased from 418,800,603.81 to 357,708,188.53, a decline of approximately 14.6%[16] - Cash and cash equivalents decreased from 192,343,847.31 to 186,794,081.84, a decrease of about 2.9%[15] - Accounts receivable decreased from 47,221,817.21 to 42,991,129.08, a decline of approximately 9.4%[16] - The company's total liabilities decreased by ¥23,000,000, reflecting a reduction in debt obligations during the reporting period[9] - Total liabilities decreased from 913,383,952.32 to 877,299,601.40, a reduction of about 4.0%[17] - The company's equity attributable to shareholders decreased from 859,104,421.04 to 833,456,095.77, a decrease of about 3.0%[17] - The company’s total liabilities and equity decreased from ¥1,792,171,860.35 to ¥1,719,382,737.43, indicating a reduction in financial leverage[18] Expenses - The company reported an increase in sales expenses by ¥19,830,000, primarily due to the acquisition of 51% of Delun Medical and the expansion into the dental medical sector[7] - The company’s management expenses increased by ¥27,770,000, also attributed to the acquisition and related business expansion[7] - The total operating costs for the first quarter were ¥124,438,676.52, up from ¥30,562,144.94, indicating an increase of 307.5%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 57,916[12] - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, holds 23.81% of shares, totaling 200,000,000 shares[12] - The number of shares held by the top ten unrestricted shareholders totals 200,000,000 and 32,263,200 shares respectively[12] Other Financial Information - The company received government subsidies amounting to ¥113,105.57, contributing to its financial performance[5] - The company reported a significant reduction in other receivables from 95,402,811.61 to 41,848,819.04, a decline of approximately 56.1%[16] - The company has not undergone an audit for the first quarter report[24]